deferoxamine has been researched along with Cranial Nerve II Diseases in 11 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eight patients (16 eyes) developed ocular toxicity while undergoing intravenous deferoxamine mesylate (Desferal) chelation therapy for transfusional hemosiderosis." | 3.67 | Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. ( Jiji, R; Lakhanpal, V; Schocket, SS, 1984) |
| "This drug is the most efficacious for treating iron overload but is associated with ocular toxicity: dose and duration related symptomatic optic neuropathy on the one hand, reversible if treatment stopped, and acute retinal involvement followed by irreversible paucisymptomatic pigmentary changes on the other hand." | 2.44 | [Retinal pigment epithelium--desferal]. ( Roulez, F, 2007) |
| "Deferoxamine is a chelating agent used in the treatment of transfusional iron overload and more recently in the diagnosis and treatment of increased aluminum body stores in chronic renal failure patients." | 1.28 | Irreversible ocular toxicity from single "challenge" dose of deferoxamine. ( Bene, C; Bene, D; Kranias, G; Manzler, A, 1989) |
| "A 4-year-old girl with juvenile chronic myeloid leukemia relapsed after an allogeneic bone marrow transplantation (BMT) and became refractory to conventional chemotherapy." | 1.27 | Deferoxamine (Desferal)-induced ocular toxicity. ( Bashara, S; Goshen, Y; Kaplinsky, C; Stark, B; Yaniv, I; Zaizov, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (45.45) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ng, WS | 1 |
| Chandra, P | 1 |
| Simon, S | 1 |
| Athanasiov, PA | 1 |
| Jain, R | 1 |
| Raymond, G | 1 |
| Gilhotra, JS | 1 |
| Pelit, A | 1 |
| Haciyakupoglu, G | 1 |
| Zorludemir, S | 1 |
| Mete, U | 1 |
| Daglioglu, K | 1 |
| Kaya, M | 1 |
| Alldredge, CD | 1 |
| Schlieve, CR | 1 |
| Miller, NR | 1 |
| Levin, LA | 1 |
| Roulez, F | 1 |
| Lakhanpal, V | 1 |
| Schocket, SS | 1 |
| Jiji, R | 1 |
| Pinna, A | 1 |
| Corda, L | 1 |
| Carta, F | 1 |
| Hamed, LM | 1 |
| Winward, KE | 1 |
| Glaser, JS | 1 |
| Schatz, NJ | 1 |
| Bene, C | 1 |
| Manzler, A | 1 |
| Bene, D | 1 |
| Kranias, G | 1 |
| Kaplinsky, C | 1 |
| Stark, B | 1 |
| Goshen, Y | 1 |
| Yaniv, I | 1 |
| Bashara, S | 1 |
| Zaizov, R | 1 |
| Orton, RB | 1 |
| de Veber, LL | 1 |
| Sulh, HM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease[NCT00769834] | 0 participants (Actual) | Observational | 2010-01-31 | Withdrawn (stopped due to All investigators have moved to different oranizations) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferoxamine and Cranial Nerve II Diseases
| Article | Year |
|---|---|
[Retinal pigment epithelium--desferal].
Topics: Animals; Deferoxamine; Humans; Injections, Intravenous; Iron Overload; Optic Nerve Diseases; Risk Fa | 2007 |
10 other studies available for deferoxamine and Cranial Nerve II Diseases
| Article | Year |
|---|---|
Optical coherence tomography in desferrioxamine ocular toxicity: a place in screening and monitoring?
Topics: Aged; Chelating Agents; Deferoxamine; Female; Humans; Optic Nerve Diseases; Retina; Tomography, Opti | 2011 |
Desferrioxamine-related ocular toxicity: a case report.
Topics: Adult; beta-Thalassemia; Deferoxamine; Diagnosis, Differential; Dose-Response Relationship, Drug; El | 2012 |
Preventative effect of deferoxamine on degenerative changes in the optic nerve in experimental retrobulbar haematoma.
Topics: Animals; Deferoxamine; Disease Models, Animal; Hematoma; Iron Chelating Agents; Nerve Degeneration; | 2003 |
Pathophysiology of the optic neuropathy associated with Friedreich ataxia.
Topics: Animals; Animals, Newborn; Anisoles; Cell Death; Cells, Cultured; Chlorides; Deferoxamine; Ferric Co | 2003 |
Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy.
Topics: Aged; Blood Transfusion; Color Perception; Deferoxamine; Female; Hemosiderosis; Humans; Male; Middle | 1984 |
Rapid recovery with oral zinc sulphate in deferoxamine-induced presumed optic neuropathy and hearing loss.
Topics: Administration, Oral; Adult; Astringents; Chelating Agents; Deferoxamine; Female; Hearing Loss, Sens | 2001 |
Optic neuropathy in uremia.
Topics: Adult; Deferoxamine; Female; Humans; Kidney Diseases; Male; Methylprednisolone; Middle Aged; Optic N | 1989 |
Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
Topics: Aluminum; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Macular Edema; Middle Aged; Optic N | 1989 |
Deferoxamine (Desferal)-induced ocular toxicity.
Topics: Blindness; Child, Preschool; Deferoxamine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL P | 1988 |
Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
Topics: Child, Preschool; Deferoxamine; Ear; Eye; Female; Hearing Loss, Sensorineural; Humans; Injections, S | 1985 |